Figures
Abstract
Valproate (valproic acid, VPA), a drug for the treatment of epilepsy and bipolar disorder, causes liver steatosis with enhanced oxidative stress. Accumulating evidences exhibite that gut microbiota plays an important role in progression of nonalcoholic fatty liver disease (NAFLD). However, whether gut microbiota contributes to VPA-caused hepatic steatosis needs to be elucidated. A mixture of five probiotics was selected to investigate their effects on liver steatosis and oxidative stress in mice orally administered VPA for 30 days. Probiotics treatment significantly attenuated the hepatic lipid accumulation in VPA-treated mice via inhibiting the expression of cluster of differentiation 36 (CD36) and distinct diacylglycerol acyltransferase 2 (DGAT2). Meanwhile, probiotics exerted a protective effect against VPA-induced oxidative stress by decreasing the pro-oxidant cytochrome P450 2E1 (CYP2E1) level and activating the Nrf2/antioxidant enzyme pathway. Moreover, VPA treatment altered the relative abundance of gut microbiota at the phylum, family and genera levels, while probiotics partially restored these changes. Spearman’s correlation analysis showed that several specific genera and family were significantly correlated with liver steatosis and oxidative stress-related indicators. These results suggest that probiotics exert their health benefits in the abrogation of liver steatosis and oxidative stress in VPA-treated mice by manipulating the microbial homeostasis.
Citation: Song W, Yan X, Zhai Y, Ren J, Wu T, Guo H, et al. (2023) Probiotics attenuate valproate-induced liver steatosis and oxidative stress in mice. PLoS ONE 18(11): e0294363. https://doi.org/10.1371/journal.pone.0294363
Editor: Juan J. Loor, University of Illinois, UNITED STATES
Received: May 17, 2023; Accepted: October 30, 2023; Published: November 16, 2023
Copyright: © 2023 Song et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting Information files.
Funding: The authors acknowledge financial support from National Natural Science Foundation of China (Project: 82104314), Natural Science Foundation of Jilin Province (Project: YDZJ202301ZYTS034). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Valproate (valproic acid, VPA) is widely prescribed to treat epilepsy and bipolar disorder in several decades. However, long-term treatment with VPA causes different degrees of hepatotoxicity from steatosis to acute liver failure [1]. Liver steatosis is the most common side effect, which occurs in 61% patients receiving VPA for more than two years [2]. If no specific treatment, liver steatosis may progress into more severe live injury such as nonalcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.
A number of studies have demonstrated that there is a close association between oxidative stress and VPA-caused liver steatosis [3–5]. VPA can enhance hepatic oxidative stress by inhibiting mitochondrial fatty acid β-oxidation or impairing ROS detoxification system [6, 7]. Our recent study found that CYP2E1 was also responsible for ROS accumulation upon VPA treatment, which Further promoted CD36-mediated lipid uptake and DGAT2-mediated triacylglycerol synthesis, causing hepatic lipid accumulation [8]. It indicates that oxidative stress contributes to VPA-caused liver steatosis.
Interestingly, serveral recent studies found that VPA administration markedly altered the composition and structure of gut microiota in both epileptic patients and rats [9, 10]. A consecutive 28-day treatment with VPA to rats significantly changed the bacterial richness and diversity with an increase in relative abundance of Actinobacteria, Firmicutes and a decrease in relative abundance of Bacteroidetes at the phylum level [9]. Meanwhile, in epileptic patient receiving VPA treatment, some gut microbiota were correlated with the alteration of liver function-related biochemical parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), cholesterol (TC) and lactate dehydrogenase (LDH) [10]. These findings suggest that there mignt be a link between gut microbiota dysbiosis and VPA-caused metabolic disorder.
Accumulating evidences point out that gut microbiota plays a critical role in the occurance and development of nonalcoholic fatty liver disease (NAFLD) [11]. Patients and animals with NAFLD had the altered composition and structure of gut microbiota at different levels [12]. Additionally, gut microbiota seems to be directly or indirectly associated with the change of redox state in the intestine or other tissue including liver [13]. Therefore, we suppose that gut microbiota modulation may be beneficial for improving hepatic oxidative stress and lipid metabolism in VPA-treated mice.
Probiotics, alive microorganisms with health benefits, have been demonstrated to exert beneficial roles in the restoration of microbial homeostasis and abrogation of NAFLD [14]. The administration of probiotics may provide a new strategy in the prevention or treatment of liver steatosis. Probiotics such as Lactobacillus, Bifidobacterium and Streptococcus had positive effects on the attenuation of NAFLD [12]. Especially, Lactobacillus and Bifidobacterium exhibited excellent antioxidative activities against oxidative stress-related diseases [15, 16]. Here we selected a mixture of five probiotics including Lactobacillus plantarum LP45, Lactobacillus paracasei YMC1069, Bifidobacterium longum L693, Bifidobacterium bifidum TMC3115 and Streptococcus thermophiles S131, and assessed their impacts on VPA-caused oxidative stress and liver steatosis in mice.
Materials and methods
Chemicals and reagents
Valproate was purchased from Sigma-Aldrich (St louis, MO, USA). Lactobacillus plantarum LP45, Lactobacillus paracasei YMC1069, Bifidobacterium longum L693, Bifidobacterium bifidum TMC3115 and Streptococcus thermophiles S131 were gifts from Hebei Yiran Biotechnology Co., Ltd.
Animals and treatment
Male C57B/6 J mice at 6 weeks of age (20–22 g) were obtained from Liaoning Changsheng biotechnology Co., Ltd (Benxi, China). All the mice had free access to food and water and housed in a specific pathogen-free cage at 25 ± 2°C, 55 ± 15% humidity, and 12-hour alternating light-dark cycle circumstance. Mice were randomly divided into control group, VPA group, probiotics group, and VPA plus probiotics group (n = 6 each group) and fed with vehicle, VPA (500 mg/kg), a mixture of five probiotics (3×108 CFU Lactobacillus plantarum LP45, 3×108 CFU Lactobacillus paracasei YMC1069, 3×108 CFU Bifidobacterium longum L693, 3×108 CFU Bifidobacterium bifidum TMC3115, and 0.5×108 CFU Streptococcus thermophiles S131), and VPA plus probiotic mixture for consecutive 30 days, respectively.
Health and behavior of mice were monitored every day.
Body weights were measured each three days. Unfortunately, one mouse in the VPA plus probiotics group accidently died during the oral administration. All the mice were killed by CO2 euthanasia 24 hours after the last administration with all efforts to minimize mice’ suffering, then serum, liver tissues or feces were harvested for further analysis. All animal protocols and experiments were approved by the Animal Ethics Committee of Jilin University, in accordance with the Guidelines for the Care and Use of Laboratory Animals of Jilin University (Protocol Number: 2021-PZ012). Everyone obtained informed written consent. All operators have received the qualifications of animal experiments and professional training in animal welfare ethics in the School of Life Sciences of Jilin University, and proficient in the relevant operating skills of this experiment.
Biochemical analysis
The TC, TG, ALT and AST levels in liver or serum were analyzed by commercial assay kits (Jiancheng Bioengineering Institute, Nanjing, China). The malondialdehyde (MDA) and glutathione (GSH) levels in liver tissues were analyzed using commercial assay kits (Solarbio, Beijing, China).
Histopathological examination and immunostaining
Fresh liver tissues were fixed in 10% formalin and embedded in paraffin. Sections at 5 μm thick were used for hematoxylin and eosin (H&E) staining and 4-hydroxy-2-nonenal (4-HNE) immunostaining. The frozen liver tissues were fixed in optimum cutting temperature (O.C.T) compound. Sections at 8 μm thick were used for Oil-red O staining. Images were collected by a microscope (IX70, Olympus, Japan) at 200-fold magnification.
qRT-PCR analysis
Total RNA was extracted from the liver of mice by a Total RNA Kit (OMEGA, Norcross, GA, USA). cDNA was synthesized from 2 μg of total RNA using the PrimeScriptTM reverse transcription reagent kit (TAKARA, Beijing, China). qRT-PCR was performed on a LightCycler®480 System (Roche, Switzerland) using SYBR green PCR Master Mix (TAKARA, Beijing, China), cDNA template, and gene-specific primers. Primer sequences for CYP2E1, FATP2, FATP5, CD36, FAS, SCD1, ACC, DGAT1, DGAT2, SREBP-1c, PXR, PPARα, PPARγ, and GAPDH were listed previously [8]. Primer sequences for HO-1, Nrf2, SOD, CAT, GST, HMGCS, HMGCR and LXR-α were shown in S1 Table. The comparative Ct (ΔΔ Ct) method was used to quantitate the relative mRNA level.
Western blot analysis
The total and nuclear protein in liver tissues were extracted using RIPA buffer containing 1 mM PMSF (Beyotime, Shanghai, China) and nuclear protein extraction kit (Solarbio, Beijing, China), respectively. Extracted proteins were separated on SDS-PAGE gels, transferred to PVDF membranes, incubated with anti-HO-1, anti-β-actin antibodies (BBI, Shanghai, China), anti-Nrf2, anti-Histone H3, anti-CD36 antibodies (Proteintech, Rosemount, IL, USA), anti-CYP2E1, anti-DGAT2 antibodies (Abcam, Cambridge, MA, USA), then visualized by the Odyssey Infrared Imaging System (Li-Cor). Densitometric quantification of protein bands was performed using Odyssey V3.0 (Li-Cor) normalized to Histone H3 or β-actin and calculated as the fold-change compared with the control group.
16s rRNA sequencing analysis
DNA was extracted from the feces of mice using a stool DNA isolation Kit (TianGen, China). Universal primers F343 (5’-TACGGRAGGCAGCAG-3’) and R789 (5’-AGGGTATVTAATCCT-3’) were used to amplify the V3-V4 regions of the bacterial 16S rRNA gene. Sequencing was performed on an Illumina MiSeq platform at Shanghai OE Biotech. Co., Ltd. After high quality reads obtained from quality filtering, the normalized operational taxonomic unit (OTU) tables were generated from chimeras removal of the raw data for diversity and statistical analyses.
Statistical analysis
Data were displayed as mean ± standard deviation. To determine the effect of VPA on the mRNA levels of some genes involved in FA uptake, FA synthesis, TG synthesis, TC metabolism and nuclear receptor, the comparision between control and VPA group was performed using the Student’s t test. For analyzing the body weight, comparisons between time-based measurements within each group were performed with analysis of variance for repeated measurement. For the other experimental studies including control, VPA, probiotics and VPA plus probiotics groups, one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test was adopted. The Spearman’s rank correlation coefficients between the relative abundance of gut microbiota and liver steatosis and oxidative stress-related indicators were determined for correlational statistical analysis. All analyses were accomplished using SPSS 20.0 (IBM SPSS), and a P value less than 0.05 was considered statistically significant.
Results
Probiotics attenuated VPA-caused liver steatosis and oxidative stress
Previous studies have demonstrated that consecutive 30-day treatment with VPA to mice caused liver steatosis [8]. Considering a close relationship between gut microbiota and NAFLD, we observed the effects of probiotics on VPA-caused liver steatosis. As shown in Fig 1A, treatment with VPA alone or in combination with probiotics significantly decreased the body weight of mice throughout the 30 days, as compared to vehicle treatment, but had no significant influences on liver weight and liver/body weight ration at the end of the experiment. Interestingly, probiotics dramatically inhibited the enhanced TC and TG contents or oil red O staining in the liver of mice after VPA treatment, indicating the decreased liver lipid accumulation by probiotics (Fig 1B). Meanwhile, the increased hepatic oxidative stress in VPA-treated mice as detected by the reduced GSH level, the elevated MDA level, and the enhanced 4-HNE immunostaining was also significantly alleviated by probiotics (Fig 1C). The H&E staining indicated the attenuated VPA-caused hepatic microvesicular steatosis in mice after co-treatment with probiotics, but the serum ALT and AST levels were comparable among the different groups (Fig 1D).
(A) Body weight, liver weight and liver/body weight ratio of mice; (B) Oil Red O staining (200x magnification), TG and TC levels in liver; (C) 4-HNE immunostaining (200x magnification), GSH and MDA levels in liver; (D) H&E staining (200x magnification), ALT and AST levels in serum. Data were expressed as the MEAN±SD.#p < 0.05, ##p < 0.01, ###p < 0.001 versus control group, &P < 0.05, &&P < 0.01, &&&P < 0.001 versus VPA group.
Probiotics decreased oxidative stress by inhibiting the pro-oxidant CYP2E1 level and activating the Nrf2/antioxidant enzyme pathway
To clarify the molecular mechanism by which probiotics decreased the oxidative stress in VPA-treated mice, we first explored the level of CYP2E1, which has been demonstrated to promote ROS production and liver steatosis in VPA-treated mice [8]. As expected, VPA treatment significantly elevated the mRNA and protein level of hepatic CYP2E1 (Fig 2A and 2B). Interestingly, probiotics treatment significantly attenuated the enhanced CYP2E1 level. Further, the levels of several antioxidant enzymes including CAT, GST, SOD, and HO-1 were evaluated. VPA treatment markedly decreased the mRNA levels or enzymatic activities of SOD, CAT or GST in liver or serum, while probiotics treatment alleviated these changes to different degrees (Fig 2G–2O). Moreover, the decreased mRNA and protein levels of HO-1 in VPA group were also significantly prevented by probiotics (Fig 2C and 2D), similar with the alteration of mRNA and nuclear protein levels of Nrf2 (Fig 2E and 2F).
(A) mRNA and (B) protein levels of CYP2E1 in liver; (C) mRNA and (D) protein levels of HO-1 in liver; (E) mRNA and (F) nuclear protein levels of Nrf2 (nNrf2) in liver; (G) Hepatic mRNA level, (H) hepatic enzymatic activities and (I) serum enzymatic activity of SOD; (J) Hepatic mRNA level, (K) hepatic enzymatic activities and (L) serum enzymatic activity of CAT; (M) Hepatic mRNA level, (N) hepatic enzymatic activities and (O) serum enzymatic activity of GST. Data were expressed as the MEAN±SD. #p < 0.05, ##p < 0.01,###p < 0.001 versus control group, &P < 0.05, &&P < 0.01, &&& P < 0.001versus VPA group.
Probiotics inhibited lipid accumulation by downregulating the CD36 and DGAT2 levels
To explore the underlying mechanism of VPA-caused lipid accumulation, the mRNA levels of some genes involved in fatty acid (FA) uptake, FA synthesis, TG synthesis, TC metabolism and nuclear receptor were analyzed by qRT-PCR method (Fig 3A). Among these selected genes, the expression of CD36 and DGAT2 was significantly upregulated upon VPA treatment, indicating the enhanced uptake of fatty acid and conversion from diglycerides into triglycerides in VPA-treated mice. Interestingly, the elevated mRNA and protein levels of both CD36 and DGAT2 were markedly inhibited by probiotics (Fig 3B and 3C). It suggests that probiotics could inhibit VPA-induced lipid accumulation via the downregulation of CD36 and DGAT2.
(A) The mRNA expression of genes involved in fatty acid (FA) uptake, FA synthesis, TG synthesis, TC metabolism and nuclear receptor in liver; (B) CD36 and DGAT2 mRNA levels in liver; (C) Protein levels of CD36 and DGAT2 in liver. Data were expressed as the MEAN±SD. #p < 0.05, ##p < 0.01 versus control group, &P < 0.05, &&P < 0.01 versus VPA group.
Probiotics recovered gut microbial community structure
The 16S rRNA gene sequencing in fecal samples was accomplished to explore the effect of probiotics on gut microbiota composition. Microbial β diversity analysis based on PCoA plot showed a clear separation of bacterial composition between VPA group and control group, while VPA plus probiotics group was clustered between them (Fig 4C). Consistently, microbial α diversity analysis indicated the significantly decreased Chao 1 index after VPA treatment and the alleviated change after its cotreatment with probiotics(Fig 4A). Differently, there was no significant differences in the levels of Shannon index among the different groups (Fig 4B). These findings reaveal that VPA treatment alters fecal bacterial community structure and lowers their richness, while probiotics treatment partially restores the alteration.
16S rRNA sequencing analysis of isolated fecal DNA across the different groups. (A) Chao1 index; (B) Shannon index; (C) Principal co-ordinates analysis (PCoA); The relative abundance of the top30 taxa at the (D) phylum, (E) family, and (F) genus levels; The relative bacterial abundance with significant difference between two groups at the (G) phylum, (H) family, and (I) genus levels. Data were expressed as the MEAN±SD. #p < 0.05, ##p < 0.01 versus control group, &P < 0.05, &&P < 0.01 versus VPA group.
Next, the relative abundance of the top30 taxa at the phylum, family or genus level was shown in the boxplot (Fig 4D–4F). At the phylum level, the abundance of Actinobacteriota, Acidobacteriota and Gemmatimonadota was higher in VPA group than in control group, whereas probiotic treatment significantly reversed the changes (Fig 4G). At the family level, VPA group had a lower abundance of Prevotellaceae, Christensenellaceae, Ruminococcaceae, [Eubacterium]_coprostanoligenes_group, Tannerellaceae or Butyricicoccaceael, and a higher abundance of Rs-E47-termite-group, Eggerthellaceae, Bukholderiaceae, Bifidobacteriaceae or Lactobacillaceae than control group (Fig 4H). Nevertheless, probiotics treatment attenuated these changes with significant differences as for Prevotellaceae and Christensenellaceae. At the genus level, the relative abundance of Prevotellaceae_UCG-001, Prevotellaceae_Ga6A1_group, Prevotella, Parabacteroides, Ruminococcus, and [Eubacterium]_coprostanoligenes_group was significantly reduced upon VPA treatment, and the decreased Prevotellaceae_UCG-001, Prevotellaceae_Ga6A1_group, Prevotella were significantly prevented by probiotics (Fig 4I).
Correlation between gut microbiota and indicators of liver steatosis or oxidative stress
The association between gut microbiota and liver steatosis- or oxidative stress- related indexes was clarified using the Spearman’s rank correlation analysis. At the family level (Fig 5A), the TG level was negatively correlated with Prevotellaceas, Oscillospiraceae, Clostridia_UCG-014, Tannerellaceae, UCG-010 and Christensenellaceae and positively correlated with Muribaculaceae, Eggerthellaceae and Rs-E47_termite_group. Also, Desulfovibrionaceae and Erysipelatoclostridiaceae were negatively associated with the TC level. Meanwhile, the MDA level had a significant positive and negative correlation with Lachnospiraceae and Erysipelotrichaceae, respectively. A negative association between Sutterellaceae and GSH level was also found.
Heatmap of Spearman’s correlation between the relative abundance of gut microbiota and liver steatosis- or oxidative stress-related indicators (A) at the family level and (B) at the genus level. Significant correlations are indicated by **p < 0.01.
At the genus level (Fig 5B), the TG level had a negative association with Prevotella, Prevotellaceae_NK3B31_group, Prevotellaceae_Ga6A1_group, Clostridia_UCG-014 or Parabacteroides, and a positive association with Muribaculaceae and Roseburia. Further, a positive relatioship between Lachnospiraceae_NK4A136_group and TC or Lachnospiraceae_UCG-001 and MDA was shown. Additionally, the GSH level was positively and negatively correlated with Prevotellaceae_UCG-001 and Parasutterella, respectively.
Discussion
Probiotics have attracted interest in improving the intestinal bacterial composition and alleviating the development of NAFLD. Our study first demonstrated that a probiotic mixture attenuated VPA-induced liver steatosis and oxidative stress by manipulating gut microbiota, which provides further insight into the potential of probiotics in hepatic health and homeostasis.
Accumulating evidences have demonstrated that gut microbiota dysbiosis contributes to the initiation and progression of NAFLD [11]. Many preclinical and clinical studies have tried to investigate a microbial signature of NAFLD. Likewise, our results showed that VPA administration to mice promoted hepatic liver steatosis and oxidative stress accompanied with the altered structure and composition of gut microbiota at the level of phylum (increased Actinobacteriota, Acidobacteriota and Gemmatimonadota), family (decreased Prevotellaceae, Christensenellaceae, Ruminococcaceae, [Eubacterium]_coprostanoligenes_group, Tannerellaceae, or Butyricicoccaceae and increased Rs-E47-termite-group, Eggerthellaceae, Bukholderiaceae, Bifidobacteriaceae and Lactobacillaceae) or genera (decreased Prevotellaceae_UCG-001, Prevotellaceae_Ga6A1_group, Prevotella, Parabacteroides, Ruminococcus, and [Eubacterium]_coprostanoligenes_group). Interestingly, among these altered taxa, some of them have been demonstrated to have a relationship with NAFLD or obese. For example, the abundance of Prevotellaceae UCG-001, Ruminococcus, Christensenellaceae, and [Eubacterium]_coprostanoligenes_group was significantly decreased in mice or human fed with high-fat diet (HFD) [17–20], similar with our results in VPA-treated mice. Consistently, the reduced abundance of Parabacteroides was observed in patients with obesity or NAFLD [21–23]. Further, some studies demonstrated that patients with NAFLD had a consistent altered bacterial signature such as the decreased abundance of Ruminococcaceae family and Prevotella genera [24], which were also found in the study, indicating that there is an overlap of bacterial signatures between VPA-caused liver steatosis and high-fat diet-caused NAFLD. In addition, the heatmaps showed a significant correlation between some specific genera and family and the levels of TG, TC, GSH or MDA, suggesting that gut microbiota dysbiosis in VPA-treated mice are associated with liver steatosis and oxidative stress.
Moreover, a growing number of studies reveal that probiotics have a beneficial role in modulating gut microbiota [14]. Probiotics are considered to be a complementary approach for treating NAFLD. As expected, our results showed that probiotics treatment inhibited VPA-induced lipid accumulation with the significant restoration of gut microbiota including phylum of Actinobacteriota, Acidobacteriota and Gemmatimonadota, family of Prevotellaceae and Christensenellaceae, or genus of Prevotellaceae_UCG-001, Prevotellaceae_Ga6A1_group, Parabacteroides and Prevotella. Among them, Prevotellaceae_UCG-001, Christensenellaceae, Prevotella, and Parabacteroides have been demonstrated to have a close relationship with NAFLD. It suggests that probiotics-caused gut microbiota restortation contributes to the alleviation of liver steatosis in VPA-treated mice.
The present study found that VPA treatment not only promoted hepatic CYP2E1 overproduction but also reduced the levels and activities of antioxidant enzymes SOD, CAT, GST, and HO-1. CYP2E1 has been demonstrated to transform ethanol or polyunsaturated fatty acids into ROS and lipid peroxidation products [25, 26]. Meanwhile, antioxidant enzymes (SOD, CAT, GST, and HO-1) have a protective role against ROS accumulation [27]. Thereby, both the enhanced CYP2E1 generation and the inactivated antioxidant enzymes contribute to VPA-caused oxidative stress. Interestingly, the supplementation of probiotics significantly reversed these changes, resulting in the impaired oxidative stress. Similarly, some studies have demonstrated that probiotics exert their health benefits through the alleviation of oxidative stress [12]. It is reported that Lactobacillus and Bifidobacterium possess excellent antioxidant capacity by stimulating the activity of host antioxidant enzymes [12]. For example, Lactobacillus plantarum KSFY02 remarkedly increased the enzymatic activities of CAT, SOD, and glutathione peroxidase in the liver of aged mice [28]. Treatment with a soy milk containing Lactobacillus plantarum A7 ameliorated oxidative stress in patients with diabetic kidney disease by elevating the levels of serum glutathione peroxidase and GSH [29]. The supplementation of probiotics containing Bifidobacterium longum CECT 7347, Lactobacillus casei CECT 9104, and Lactobacillus rhamnosus CECT 8361 enhanced ROS neutralization and plasma antioxidant levels in male cyclists [30]. Collectively, it is considered that the antioxidant capacity of Lactobacillus and Bifidobacterium is responsible for the reduced hepatic oxidative stress after probiotics treatment.
Also, we found that the mRNA and protein levels of nuclear Nrf2, a transcript factor of SOD, CAT, GST, and HO-1 were significantly upregulated after co-treatment with probiotics and VPA, suggesting Nrf2 has a positive role in the antioxidant capacity of probiotics, which has also been shown in two other studies [31–33]. One study exhibited the protective role of probiotics against oxidative stress by modulating the Nrf2-Keap1-ARE pathway [31]. The other study found that Lactobacillus rhamnosus GG treatment inhibited acetaminophen- or ethanol- caused acute oxidative liver damage in mice via upregulating the hepatic Nrf2 expression [33]. The molecular mechanism may be explained by the interaction of microbial metabolites with host receptors such as Toll-like receptors, which activates Nrf2-Keap1-ARE pathway and then promote the antioxidant enzyme expression.
In addition, VPA treatment caused liver steatosis accompanied with the upregulation of CD36 and DGAT2. CD36 is a transmembrane lipid transporter that promotes long-chain fatty acid uptake [34]. DGAT2 is a rate-limiting enzyme responsible for the transformation of diglycerides to triglycerides [35]. Thus, it suggests that the elevated CD36 and DGAT2 levels contribute to VPA-induced liver steatosis, which is further supported by the improved lipid deposit and the decreased CD36/ DGAT2 levels after probiotics treatment. Combined with previous research reavealing that oxidative stress is responsiple for the upregulation of CD36 and DGAT2 [36, 37], it is considered that probiotics could provide a certain degree of protection against VPA-caused liver steatosis through the alleviation of oxidative stress. Indeed, several preclinical studies have demonstrated that probiotics prevent NAFLD development by reducing oxidative stress [12, 38, 39]. Li and his colleagues found that Lactobacillus plantarum NCU116 played a beneficial role in NAFLD rats via the inhibition of oxidative stress and the restoration of gut microbiota [38]. Also, treatment with Lactobacillus plantarum NA136 to mice alleviated NAFLD by promoting antioxidant system and modulating fatty acid metabolism [39].
The 16s rRNA sequencing results showed that VPA treatment significantly lowered the abundance of several butyrating-producing bacteria such as Prevotellaceae_UCG-001, Prevotellaceae_Ga6A1_group, [Eubacterium]_coprostanoligenes_group, Ruminococcaceae or Christensenellaceae [40–46]. To our attention, previous studies showed that butyrate significantly inhibited lipid deposit and oxidative stress in VPA-caused liver injury or insulin-resistant obese mice [47, 48]. We suppose that the butyrate might contribute to liver steatosis and oxidative stress in VPA-treated mice. Subsequently, we analyzed the short chain fatty acids (SCFAs) levels in the feces of mice by GC-MS. Surprisingly, there was no significant differences in the levels of butyric acid, valeric acid, propionic acid and acetic acid among the different groups S1 Fig, indicating that SCFAs might not be implicated in the alteration of hepatic fat accumulation and oxidative stress in the study. In addition, we also found that the mRNA levels of hepatic proinflammatory cytokines such as IL-6 and IL-1β were significantly downregulated in VPA group relative to control group S2 Fig, suggesting that VPA-caused liver steatosis and oxidative stress might not be associated with the inflammation. The molecular mechanism underlying the alleviation of VPA-caused liver steatosis and oxidative stress by probiotics remains to be verified in the future.
Conclusions
The mixed probiotics intervention alleviated oxidative stress and lipid metabolic disorder in VPA-treated mice by inhibiting the pro-oxidant CYP2E1 level, activating the Nrf2/antioxidant enzyme pathway, and decreasing the CD36 and DGAT2 levels, accompanied with the restoration of gut microbiota dysbiosis. The data provide the evidence of probiotics efficacy and its potential utility in the prevention of liver steatosis.
Supporting information
S1 Fig. Effects of VPA and probiotics on the short chain fatty acids (SCFAs) levels in mice.
The levels of acetic acid (A), propionic acid (B), butyric acid (C), and valeric acid (D) in the feces of mice treated with vehicle, VPA, probiotics or in combination were analyzed by GC-MS method. Data were expressed as the MEAN±SD.
https://doi.org/10.1371/journal.pone.0294363.s001
(TIF)
S2 Fig. Effect of VPA on the expression of pro-inflammatory cytokines in mice.
The mRNA levels of IL-6 and IL-1β in the liver of mice treated with vehicle or VPA were analyzed by qRT-PCR method. Data were expressed as the MEAN±SD, ##p < 0.01 versus control group.
https://doi.org/10.1371/journal.pone.0294363.s002
(TIF)
Acknowledgments
We thank Hong Zhang from the First Hospital of Jilin University for providing data analysis guidance in our experiment.
References
- 1. Guo HL, Jing X, Sun JY, Hu YH, Xu ZJ, Ni MM, et al. Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update. Curr Pharm Des. 2019;25(3):343–351. pmid:30931853.
- 2. Luef GJ, Waldmann M, Sturm W, Naser A, Trinka E, Unterberger I, et al. Valproate therapy and nonalcoholic fatty liver disease. Ann Neurol. 2004;55(5):729–732. pmid:15122714.
- 3. Gai Z, Krajnc E, Samodelov SL, Visentin M, Kullak-Ublick GA. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress. Mol Pharmacol. 2020;97(5):314–323. pmid:32098797.
- 4. Tong V, Teng XW, Chang TK, Abbott FS. Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci. 2005;86(2):427–435. pmid:15858223.
- 5. van Breda SGJ, Claessen SMH, van Herwijnen M, Theunissen DHJ, Jennen DGJ, de Kok T, et al. Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018;393:160–170. pmid:29154799.
- 6. Aires CC, Ijlst L, Stet F, Prip-Buus C, de Almeida IT, Duran M, et al. Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. Biochem Pharmacol. 2010;79(5):792–799. pmid:19854160.
- 7. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327. pmid:29936596.
- 8. Ma L, Wang Y, Chen X, Zhao L, Guo Y. Involvement of CYP2E1-ROS-CD36/DGAT2 axis in the pathogenesis of VPA-induced hepatic steatosis in vivo and in vitro. Toxicology. 2020;445:152585. pmid:33007364.
- 9. Cussotto S, Strain CR, Fouhy F, Strain RG, Peterson VL, Clarke G, et al. Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. Psychopharmacology (Berl). 2019;236(5):1671–1685. pmid:30155748.
- 10. Gong X, Liu Y, Liu X, Li AQ, Guo KD, Zhou D, et al. Analysis of gut microbiota in patients with epilepsy treated with valproate: Results from a three months observational prospective cohort study. Microb Pathog. 2022;162:105340. pmid:34883229.
- 11. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412–425. pmid:27273168.
- 12. Campagnoli LIM, Marchesi N, Vairetti M, Pascale A, Ferrigno A, Barbieri A. Age-Related NAFLD: The Use of Probiotics as a Supportive Therapeutic Intervention. Cells. 2022;11(18):2827. pmid:36139402.
- 13. Averina OV, Poluektova EU, Marsova MV, Danilenko VN. Biomarkers and Utility of the Antioxidant Potential of Probiotic Lactobacilli and Bifidobacteria as Representatives of the Human Gut Microbiota. Biomedicines. 2021;9(10):1340. pmid:34680457.
- 14. Lin WY, Lin JH, Kuo YW, Chiang PR, Ho HH. Probiotics and their Metabolites Reduce Oxidative Stress in Middle-Aged Mice. Curr Microbiol. 2022;79(4):104. pmid:35157139.
- 15. Mishra V, Shah C, Mokashe N, Chavan R, Yadav H, Prajapati J. Probiotics as potential antioxidants: a systematic review. J Agric Food Chem. 2015;63(14):3615–3626. pmid:25808285.
- 16. Nowak A, Paliwoda A, Błasiak J. Anti-proliferative, pro-apoptotic and anti-oxidative activity of Lactobacillus and Bifidobacterium strains: A review of mechanisms and therapeutic perspectives. Crit Rev Food Sci Nutr. 2019;59(21):3456–3467. pmid:30010390.
- 17. Zheng Z, Lyu W, Ren Y, Li X, Zhao S, Yang H, et al. Allobaculum Involves in the Modulation of Intestinal ANGPTLT4 Expression in Mice Treated by High-Fat Diet. Front Nutr. 2021;8:690138. pmid:34095196.
- 18. Kong C, Gao R, Yan X, Huang L, Qin H. Probiotics improve gut microbiota dysbiosis in obese mice fed a high-fat or high-sucrose diet. Nutrition. 2019;60:175–184. pmid:30611080.
- 19. Stenman LK, Burcelin R, Lahtinen S. Establishing a causal link between gut microbes, body weight gain and glucose metabolism in humans—towards treatment with probiotics. Benef Microbes. 2016;7(1):11–22. pmid:26565087.
- 20. Wan Y, Tong W, Zhou R, Li J, Yuan J, Wang F, et al. Habitual animal fat consumption in shaping gut microbiota and microbial metabolites. Food Funct. 2019;10(12):7973–7982. pmid:31776537.
- 21. Palmas V, Pisanu S, Madau V, Casula E, Deledda A, Cusano R, et al. Gut microbiota markers associated with obesity and overweight in Italian adults. Sci Rep. 2021;11(1):5532. pmid:33750881.
- 22. Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65(2):451–464. pmid:27028797.
- 23. Gallardo-Becerra L, Cornejo-Granados F, García-López R, Valdez-Lara A, Bikel S, Canizales-Quinteros S, et al. Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children. Microb Cell Fact. 2020;19(1):61. pmid:32143621.
- 24. Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279–297. pmid:32152478.
- 25. Abdelmegeed MA, Ha SK, Choi Y, Akbar M, Song BJ. Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances. Curr Mol Pharmacol. 2017;10(3):207–225. pmid:26278393.
- 26. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. Arch Toxicol. 2009;83(6):519–548. pmid:19448996.
- 27. Raja S, Ahamed KF, Kumar V, Mukherjee K, Bandyopadhyay A, Mukherjee PK. Antioxidant effect of Cytisus scoparius against carbon tetrachloride treated liver injury in rats. J Ethnopharmacol. 2007;109(1):41–47. pmid:16930896.
- 28. Zhao X, Yi R, Zhou X, Mu J, Long X, Pan Y, et al. Preventive effect of Lactobacillus plantarum KSFY02 isolated from naturally fermented yogurt from Xinjiang, China, on d-galactose-induced oxidative aging in mice. J Dairy Sci. 2019;102(7):5899–5912. pmid:31103296.
- 29. Miraghajani M, Zaghian N, Mirlohi M, Feizi A, Ghiasvand R. The Impact of Probiotic Soy Milk Consumption on Oxidative Stress Among Type 2 Diabetic Kidney Disease Patients: A Randomized Controlled Clinical Trial. J Ren Nutr. 2017;27(5):317–324. pmid:28579313.
- 30. Sánchez Macarro M, Ávila-Gandía V, Pérez-Piñero S, Cánovas F, García-Muñoz AM, Abellán-Ruiz MS, et al. Antioxidant Effect of a Probiotic Product on a Model of Oxidative Stress Induced by High-Intensity and Duration Physical Exercise. Antioxidants (Basel). 2021;10(2):323 pmid:33671691.
- 31. Feng T, Wang J. Oxidative stress tolerance and antioxidant capacity of lactic acid bacteria as probiotic: a systematic review. Gut Microbes. 2020;12(1):1801944. pmid:32795116.
- 32. Wang Y, Wu Y, Wang Y, Xu H, Mei X, Yu D, et al. Antioxidant Properties of Probiotic Bacteria. Nutrients. 2017;9(5):521. pmid:28534820.
- 33. Saeedi BJ, Liu KH, Owens JA, Hunter-Chang S, Camacho MC, Eboka RU, et al. Gut-Resident Lactobacilli Activate Hepatic Nrf2 and Protect Against Oxidative Liver Injury. Cell Metab. 2020;31(5):956–968.e5. pmid:32213347.
- 34. Hames KC, Vella A, Kemp BJ, Jensen MD. Free fatty acid uptake in humans with CD36 deficiency. Diabetes. 2014;63(11):3606–3614. pmid:24917573.
- 35. Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, et al. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci U S A. 1998;95(22):13018–13023. pmid:9789033.
- 36. Jung S, Choi M, Choi K, Kwon EB, Kang M, Kim DE, et al. Inactivation of human DGAT2 by oxidative stress on cysteine residues. PLoS One. 2017;12(7):e0181076. pmid:28700690.
- 37. Liu J, Yang P, Zuo G, He S, Tan W, Zhang X, et al. Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress. Lipids Health Dis. 2018;17(1):153. pmid:30016988.
- 38. Li C, Nie SP, Zhu KX, Ding Q, Li C, Xiong T, et al. Lactobacillus plantarum NCU116 improves liver function, oxidative stress and lipid metabolism in rats with high fat diet induced non-alcoholic fatty liver disease. Food Funct. 2014;5(12):3216–3223. pmid:25317840.
- 39. Zhao Z, Wang C, Zhang L, Zhao Y, Duan C, Zhang X, et al. Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway. Appl Microbiol Biotechnol. 2019;103(14):5843–5850. pmid:31115630.
- 40. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107(33):14691–14696. pmid:20679230.
- 41. Zhang J, Guo Z, Xue Z, Sun Z, Zhang M, Wang L, et al. A phylo-functional core of gut microbiota in healthy young Chinese cohorts across lifestyles, geography and ethnicities. Isme j. 2015;9(9):1979–1990. pmid:25647347.
- 42. Berni Canani R, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R, et al. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. Isme j. 2016;10(3):742–750. pmid:26394008.
- 43. Schwingel WR, Bates DB. Use of sodium dodecyl sulfate polyacrylamide gel electrophoresis to measure degradation of soluble soybean proteins by Prevotella ruminicola GA33 or mixed ruminal microbes in vitro. J Anim Sci. 1996;74(2):475–482. pmid:8690685.
- 44. Nielsen TS, Lærke HN, Theil PK, Sørensen JF, Saarinen M, Forssten S, et al. Diets high in resistant starch and arabinoxylan modulate digestion processes and SCFA pool size in the large intestine and faecal microbial composition in pigs. Br J Nutr. 2014;112(11):1837–1849. pmid:25327182.
- 45. Haro C, Garcia-Carpintero S, Alcala-Diaz JF, Gomez-Delgado F, Delgado-Lista J, Perez-Martinez P, et al. The gut microbial community in metabolic syndrome patients is modified by diet. J Nutr Biochem. 2016;27:27–31. pmid:26376027.
- 46. Si X, Shang W, Zhou Z, Strappe P, Wang B, Bird A, et al. Gut Microbiome-Induced Shift of Acetate to Butyrate Positively Manages Dysbiosis in High Fat Diet. Mol Nutr Food Res. 2018;62(3). pmid:29178599.
- 47. Pirozzi C, Lama A, Annunziata C, Cavaliere G, De Caro C, Citraro R, et al. Butyrate prevents valproate-induced liver injury: In vitro and in vivo evidence. Faseb j. 2020;34(1):676–690. pmid:31914696.
- 48. Mollica MP, Mattace Raso G, Cavaliere G, Trinchese G, De Filippo C, Aceto S, et al. Butyrate Regulates Liver Mitochondrial Function, Efficiency, and Dynamics in Insulin-Resistant Obese Mice. Diabetes. 2017;66(5):1405–1418. pmid:28223285.